Market Overview

Data Sheet on Conjugate Vaccine Market 2018-2023, With an Expected CAGR of 14.6% - ResearchAndMarkets.com

Share:

The "Data
Sheet on Conjugate Vaccine Market (2018-2023)"
report has been
added to ResearchAndMarkets.com's offering.

The global market for conjugate vaccines will expand at a CAGR of 14.6%
to reach a value of USD 100.59 Bn by 2023.

Increased adoption of therapeutic vaccines for cancer, improved patient
compliance, a larger product pipeline, and efforts to promote adoption
of screening methods are some of the factors that will lead to the
growth of the market. The Asia-Pacific market will exhibit the highest
growth rate.

The vaccines are classified based on the diseases that they are target
at - such as pneumococcal, haemophilus influenza type b,
diphtheria-tetanus-pertussis, meningococcal, and others - and on the end
users, into pediatric and adults. Technological advancements and regular
vaccination programs by authorities are some of the factors that will
help overcome the challenges posed by lack of awareness, shortages,
uncertainty about future initiatives, and costs. Companies like
GlaxoSmithKline, Pfizer Inc., Sanofi Pasteur, and Novartis are some of
the major players operating in the market.

The subsequent information conveyed will be on an Excel sheet, presented
in an easily identifiable format.

Companies Mentioned

  • GlaxoSmithKline
  • Pfizer Inc.
  • Merck & Co.
  • Novartis
  • Sanofi Pasteur
  • CSL Limited
  • Bharat Biotech International
  • Biological E Limited
  • Serum Institute of India

For more information about this report visit https://www.researchandmarkets.com/research/xhz3cc/data_sheet_on?w=4

View Comments and Join the Discussion!